home / stock / ovid / ovid articles
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improvi...
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern ...
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class G...
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines...
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines ...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...
2024-06-18 10:30:03 ET B. Riley analyst issues BUY recommendation for OVID on June 18, 2024 09:12AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7744 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-18 07:15:06 ET BTIG analyst issues BUY recommendation for OVID on June 18, 2024 04:51AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7896 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst r...